ArdorComm Media Group

Monday, July 21, 2025 1:58 PM

Health & Wellness Community

ICMR Opens Door for Commercial Production of Next-Gen Malaria Vaccine

Ardorcomm news

The Indian Council of Medical Research (ICMR) has announced a major step forward in the fight against malaria by inviting expressions of interest (EoI) from eligible companies and manufacturers for the commercial production of a breakthrough malaria vaccine, AdFalciVax. Developed by the ICMR’s Regional Medical Research Centre in Bhubaneswar, this recombinant chimeric multi-stage vaccine targets Plasmodium falciparum, the deadliest malaria parasite, offering both individual protection and reduced community transmission. Pre-clinical validation of the vaccine technology was carried out in collaboration with ICMR-NIMR (National Institute of Malaria Research), other ICMR institutes, and the National Institute of Immunology in Delhi, which operates under the Department of Biotechnology. ICMR-RMRCBB will provide technical know-how and hands-on support throughout the vaccine production process to ensure a smooth and efficient pathway to commercialisation. Furthermore, ICMR’s team of seasoned scientists will assist in product development, study design, protocol development, data and results analysis, efficacy and safety assessments, and necessary improvements, based on mutual agreement with the collaborating partner. This initiative marks a significant stride in India’s effort to eliminate malaria through indigenous innovation and collaborative biotech development. Source: PTI

ICMR Opens Door for Commercial Production of Next-Gen Malaria Vaccine Read More »

UK Scientists Achieve Breakthrough with Birth of 8 Healthy Babies Using Three-Person IVF

Ardorcomm news

In a landmark achievement for reproductive medicine, British researchers have successfully delivered eight babies free of mitochondrial disease through an advanced fertility technique known as three-person IVF. This innovative procedure combines the genetic material of two parents with healthy mitochondria from a donor egg, offering new hope to families battling hereditary mitochondrial conditions. The pioneering work was conducted at Newcastle University, which remains the only UK clinic licensed to perform the treatment under regulations set by the Human Fertilisation and Embryology Authority (HFEA). Among 22 high-risk women who underwent the procedure, seven pregnancies were successful, leading to the birth of eight healthy infants—four boys and four girls, including one set of twins. How Three-Person IVF Works Also referred to as mitochondrial donation, the procedure involves extracting the nuclear DNA from a fertilized egg—containing genetic material from both biological parents—and transferring it into a donor egg that has had its nucleus removed but retains healthy mitochondria. This creates an embryo with the parents’ genes and functional mitochondria from the donor. Because mitochondrial DNA accounts for just a tiny fraction (0.02–1%) of the total genome, this method does not influence the child’s physical traits or personality. Instead, it eliminates the risk of severe, often fatal diseases associated with dysfunctional mitochondria, such as organ failure or neurological disorders. Clinical Results and Safety The clinical data is promising. Five of the eight babies showed no trace of mutated mitochondria, while the remaining three had only minimal levels (5–16%)—well below the 80% threshold that typically leads to disease. All infants are developing normally, hitting age-appropriate milestones, with only a few minor, non-mitochondrial-related health issues reported. These results, published in the New England Journal of Medicine, affirm the therapy’s safety and efficacy in preventing genetic transmission of mitochondrial disorders. A Regulated Path Forward The UK became the first nation to legalize mitochondrial donation in 2015, with clinical implementation starting in 2017. Since then, only women who are highly likely to pass on mitochondrial diseases have been approved for treatment, and each case is subject to rigorous ethical and medical review. By mid-2025, around 35 women had been cleared to receive this therapy. A Future of Promise and Caution While this scientific milestone brings much-needed optimism to affected families—some of whom have lost children to mitochondrial disease—experts are advocating for continued long-term follow-up. This is especially important because mitochondrial DNA is inherited maternally, meaning that any girls born from this technique could pass the donor mitochondria on to future generations. The balance between innovation and caution remains vital, but the success of these eight births signals a significant step toward eradicating certain inherited diseases and advancing assisted reproduction. Source: TOI

UK Scientists Achieve Breakthrough with Birth of 8 Healthy Babies Using Three-Person IVF Read More »

India Nears Completion of Phase-3 Trials for Indigenous Dengue Vaccine: ICMR

India is on the cusp of a major public health milestone, with nearly 8,000 out of a targeted 10,000 participants already enrolled in Phase-3 clinical trials of the country’s first homegrown dengue vaccine, as per the Indian Council of Medical Research (ICMR). Dr. Manoj Murhekar, Director of ICMR’s National Institute of Epidemiology in Chennai, confirmed the progress in an interaction with The Hindu. The large-scale trials, which are being conducted at 20 different centres across the country, are testing the efficacy of DengiAll, a tetravalent vaccine developed by Panacea Biotec. This formulation aims to provide protection against all four known dengue virus serotypes that co-circulate in various parts of India. “An effective vaccine must be able to offer strong immunity against all four strains,” Dr. Murhekar emphasized. The ICMR is the primary funder of the project, with Panacea Biotec offering partial financial and technical support. Once vaccinated, participants will be monitored for a period of two years at locations including Delhi, Hyderabad, Pune, and Chennai. Currently, there is no approved vaccine or antiviral treatment for dengue in India, despite the disease being a recurring and widespread health issue. India remains among the top 30 countries most affected by dengue, according to the World Health Organization (WHO). By the end of 2023, over 129 countries had reported cases of dengue globally. The candidate vaccine, DengiAll, is derived from the TV003/TV005 tetravalent strain originally created by the U.S.-based National Institutes of Health. Panacea Biotec is one of three Indian firms granted access to the strain and has advanced furthest in the development process. The company completed early-stage (Phase-1 and 2) trials in 2018–19, which delivered encouraging results. It also holds a process patent for its unique formulation. The Union Health Ministry highlighted that the first participant in the Phase-3 trial received a dose at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak last year. Dengue poses a significant health threat in India. Although 75–80% of infections are asymptomatic, individuals can still spread the virus via Aedes mosquito bites. Among symptomatic cases—comprising about 20–25%—children face an elevated risk of severe outcomes, including hospitalization and death. In adults, the disease can escalate into life-threatening conditions such as dengue hemorrhagic fever and dengue shock syndrome. The challenge of controlling the virus is compounded by the presence of four distinct serotypes, each offering limited cross-immunity, making repeated infections common. With the success of this trial, India could soon have its first domestically developed and licensed dengue vaccine, marking a crucial step forward in the country’s fight against vector-borne diseases. Source: The Hindu  

India Nears Completion of Phase-3 Trials for Indigenous Dengue Vaccine: ICMR Read More »

India May Face Over 1.6 Million Gastric Cancer Cases, Global Study Warns

A new international study published in Nature Medicine has sounded the alarm over a possible surge in gastric cancer cases, predicting that more than 15 million individuals born between 2008 and 2017 could develop the disease globally during their lifetime. India is projected to bear a significant burden, second only to China, with an estimated 1.6 million cases if current prevention efforts remain unchanged. The research, led by the International Agency for Research on Cancer (IARC), the cancer research wing of the World Health Organization, used global cancer incidence data from GLOBOCAN 2022 along with UN demographic forecasts. It found that nearly two-thirds of future gastric cancer cases will likely emerge in Asia, with India and China alone expected to contribute about 6.5 million new diagnoses. A key finding of the study highlights that 76% of these cases could be linked to Helicobacter pylori—a widespread and chronic bacterial infection of the stomach that significantly increases cancer risk. Despite being preventable and treatable, H. pylori remains a major health challenge in many countries. Gastric cancer is currently the fifth most deadly cancer worldwide. The study also points to an anticipated six-fold rise in cases across sub-Saharan Africa, where the current incidence is relatively low. Experts behind the research are urging governments to invest in large-scale preventive measures—especially in screening and treatment programs targeting H. pylori. They stress that such interventions could slash future cancer cases by as much as 75%. The researchers warn that an ageing global population, along with rising cancer rates in younger people, could undo recent progress in cancer control if swift action is not taken. The findings reinforce the urgent need for countries, particularly in Asia, to enhance public health strategies focusing on early diagnosis, education, and bacterial eradication to curb the looming threat of gastric cancer. Source: CNBCTV18

India May Face Over 1.6 Million Gastric Cancer Cases, Global Study Warns Read More »

Planned C-Sections May Increase Childhood Leukaemia Risk, Study Finds

A recent study from Sweden suggests that babies delivered through planned caesarean sections may face a higher risk of developing leukaemia—specifically acute lymphoblastic leukaemia (ALL)—compared to those born via emergency C-sections or vaginal delivery. The study, conducted by researchers at Karolinska Institutet and published in The International Journal of Cancer, analysed health data from nearly 2.5 million children born between 1982–1989 and 1999–2015, using Sweden’s Medical Birth Register. Of the total births, around 375,000 (15.5%) were delivered through C-sections. Among these, 1,495 children were later diagnosed with leukaemia. The researchers found that children born via C-section had a 7% higher risk of developing acute lymphoblastic leukaemia compared to those born vaginally. Notably, when comparing types of C-sections, those delivered by planned (elective) C-section faced a 21% increased risk of ALL than those born through emergency C-sections. One possible explanation, the study suggests, lies in the differing levels of exposure to beneficial bacteria and birth stress. Emergency C-sections typically occur after the onset of labour, and if the amniotic sac has ruptured, the baby is partially exposed to vaginal microbes and the physical stress of labour—factors that might positively influence immune development. Planned C-sections, on the other hand, are often scheduled before labour begins, limiting such exposure. Lead researcher Christina-Evmorfia Kampitsi emphasized that the findings shouldn’t cause undue concern for mothers who require medically necessary C-sections. However, she noted that the results support existing research indicating that planned C-sections may also be linked to increased risks of asthma, allergies, and type 1 diabetes in children. “These insights strengthen the case for carefully evaluating the necessity of non-medically indicated planned caesarean deliveries,” Kampitsi said. The study contributes to a growing body of evidence exploring how early-life exposures—especially those related to birth methods—may influence long-term health outcomes, including the development of childhood cancers such as acute lymphoblastic leukaemia. Source: PTI

Planned C-Sections May Increase Childhood Leukaemia Risk, Study Finds Read More »

No Proven Link Between COVID-19 Vaccines and Sudden Deaths, Confirms Union Health Ministry

The Union Ministry of Health and Family Welfare has clarified that there is no scientific evidence connecting COVID-19 vaccination with sudden or unexplained deaths in India. This conclusion is backed by comprehensive studies conducted by the Indian Council of Medical Research (ICMR) and the National Centre for Disease Control (NCDC). In an official statement, the Ministry emphasized that extensive investigations were carried out across the country by multiple research agencies to examine reports of sudden deaths, particularly among seemingly healthy young adults. Findings from these studies have consistently shown no direct association between COVID-19 vaccines and such fatalities. Two key studies have been pivotal in reaching this conclusion. The first, undertaken by ICMR’s National Institute of Epidemiology (NIE), is a multicentric matched case-control study titled “Factors associated with unexplained sudden deaths among adults aged 18–45 years in India.” Conducted across 47 tertiary hospitals in 19 states and union territories from May to August 2023, the research analyzed cases between October 2021 and March 2023. The outcome was clear: COVID-19 vaccination does not increase the risk of sudden death in young, otherwise healthy adults. The second study, still in progress, is being led by AIIMS, New Delhi, with ICMR’s collaboration and support. This prospective research—“Establishing the cause in sudden unexplained deaths in young”—aims to pinpoint the most common reasons behind such fatalities. Preliminary data reveals that heart attacks (myocardial infarctions) remain the leading cause of sudden death in this demographic, with no significant shift in trends compared to previous years. In many cases, genetic factors have also emerged as likely contributors. These studies offer valuable insights into sudden deaths among young individuals and provide reassurance about the safety of COVID-19 vaccines. Researchers highlight that deaths may stem from a range of issues, including underlying health conditions, genetic predispositions, and unhealthy lifestyles, rather than vaccination. Public health experts have strongly criticized unverified claims linking vaccines to sudden deaths, calling them unscientific and dangerous. Such misinformation not only lacks factual basis but also poses a serious risk to public trust and could foster vaccine hesitancy, undermining one of the most effective tools used during the pandemic to save lives. The government reaffirmed its commitment to science-driven public health policies and continued research to safeguard the health and well-being of all citizens. Source: ANI

No Proven Link Between COVID-19 Vaccines and Sudden Deaths, Confirms Union Health Ministry Read More »

India’s Urgent Need for 15,000 Family Doctors Annually by 2030 Highlights Training Crisis

A landmark national survey has revealed a critical shortfall in India’s ability to train enough family physicians to meet its growing healthcare needs. By 2030, the country will require around 15,000 new family doctors each year, yet it currently lacks the infrastructure and educational capacity to fulfill that demand — especially for rural areas, where 39.3% of current family physicians serve. The extensive survey, conducted across 28 states and union territories, gathered insights from 272 family physicians, providing a rare nationwide snapshot of the realities faced by India’s frontline primary care providers. Survey Highlights: 48.3% of respondents are engaged in primary care, debunking the belief that family doctors mainly operate in urban hospitals. 68.9% are involved in inpatient hospital care, while 56.3% provide emergency services. 66.2% conduct home visits, and 62% are involved in palliative care. 44.7% of surveyed doctors are women, indicating a positive trend toward gender balance in the field. Despite their wide-ranging and critical contributions — from delivering babies to performing minor surgeries — family doctors remain undervalued and under-supported within India’s healthcare system. Dr. Raman Kumar, Founding President of the Academy of Family Physicians of India (AFPI), emphasized the findings: “Family doctors are vital community-based care providers, yet face a severe shortage of training programs and clear career pathways.” Although the National Medical Commission Act of 2019 mandates family medicine as a core discipline, its implementation has been patchy. The survey calls for urgent action, including increasing MD and DNB seats in family medicine, formally recognizing the discipline across teaching hospitals, and embedding family physicians in both public and private healthcare systems. Dr. Archna Gupta, a clinician scientist at St. Michael’s Hospital in Canada, stated, “This data gives policymakers a clear direction. Strengthening family medicine is essential for building an equitable and robust healthcare system.” Dr. Ramakrishna Prasad, Chair of AFPI’s National Centre for Primary Care Research, echoed this, adding, “We must make family medicine a credible and aspirational choice for future doctors if we hope to build a resilient healthcare network.” Coinciding with National Doctors’ Day 2025, themed “Behind the Mask: Caring for Caregivers,” the survey sheds light on the often-overlooked yet indispensable role of family physicians. Despite repeated policy endorsements—from the 2002 National Health Policy to the NRHM taskforces—family medicine remains neglected in practice. This evidence-backed report stands as a stark reminder: Without substantial investment in family medicine education and infrastructure, India cannot achieve universal health coverage or bridge the rural-urban healthcare divide. Source: Economic Times  

India’s Urgent Need for 15,000 Family Doctors Annually by 2030 Highlights Training Crisis Read More »

Indigenous Kit Developed for Accurate, Rapid Detection of Nipah Virus: ICMR-NIV

In a significant stride for India’s healthcare innovation, the Indian Council of Medical Research (ICMR) has unveiled a homegrown rapid diagnostic kit capable of detecting the Nipah virus with complete accuracy. Designed for swift deployment in the field, the portable test delivers results in just 1 to 2 hours without the need for sophisticated laboratory equipment. Dr. Naveen Kumar, Director of ICMR’s National Institute of Virology (NIV) in Pune, highlighted the effectiveness of the kit, stating, “It is 100% sensitive and specific, relying on the amplification of the viral gene without requiring specialised machinery.” The cost-effective test is priced at ₹250 and is based on the Loop-mediated Isothermal Amplification (LAMP) assay technique. The Nipah virus, a highly lethal zoonotic pathogen with a mortality rate of approximately 50%, is primarily transmitted to humans from fruit bats. It can also spread via contaminated food or human-to-human contact. Symptoms of the infection range from mild flu-like signs to severe respiratory distress and encephalitis, often proving fatal. Recent outbreaks of the disease, particularly the 2023 episode in Kerala’s Kozhikode district, underscore the urgent need for swift and reliable diagnostics. ICMR is concurrently collaborating with Zydus Health Sciences (Ahmedabad) and the Translational Health Science and Technology Institute (Faridabad) on the development of monoclonal antibodies. Efforts are also underway to create an indigenous vaccine for the virus. NIV remains the only laboratory in India equipped to culture the Nipah virus, making it central to the country’s disease surveillance and response capabilities. Source: ANI

Indigenous Kit Developed for Accurate, Rapid Detection of Nipah Virus: ICMR-NIV Read More »

Delhi Govt to Boost Healthcare with More Dialysis Machines, Imaging Services via PPP Model

The Delhi government is set to enhance its public healthcare system by adding over 30 new dialysis machines, expanding access to diagnostic services like MRI, CT scans, and ultrasounds through the Public-Private Partnership (PPP) model, and constructing rest houses (VishramGrih) for patients and their caregivers, according to senior officials. These initiatives were reviewed during a key meeting of the Health Department held on June 18, chaired by Delhi Health Minister Pankaj Kumar Singh. The meeting focused on strengthening medical infrastructure and service delivery in the national capital. As part of its ongoing efforts under the Pradhan Mantri National Dialysis Programme (PMNDP) operating via the PPP model, the government has already deployed 150 dialysis machines across 16 public hospitals. Singh confirmed that an additional 32 to 40 machines will soon be installed to meet growing demand. Officials also assessed progress on various health schemes and facilities, including the operationalisation of Ayushman Arogya Mandirs, the development of critical care units under the PM-Ayushman Bharat Health Infrastructure Mission (PM-ABHIM), and the rollout of Jan Aushadhi Kendras to ensure affordable medicine availability. Other key issues on the agenda included the outsourcing of registration services in outpatient (OPD) and inpatient (IPD) departments, addressing manpower shortages in hospitals and Mohalla Clinics, implementing the Hospital Information Management System (HIMS), and ensuring smooth procurement of essential medical supplies. In addition, the Health Minister directed the formation of new health councils and committees, and stressed the identification of sensitive roles within the health department to improve transparency and governance. A senior official noted that the minister has issued strict deadlines, with most initiatives expected to be completed within the next three to four weeks or by the following month. These efforts reflect the Delhi government’s renewed push to modernize its healthcare delivery system and improve patient experience across the city. Source: PTI

Delhi Govt to Boost Healthcare with More Dialysis Machines, Imaging Services via PPP Model Read More »

Indian Researchers Pioneer Breakthrough Nano-Cup Technology for Heat-Based Cancer Treatment

In a major leap for non-invasive cancer therapies, Indian scientists have unveiled a revolutionary method to create nano-sized cup-shaped particles that can eliminate tumors using heat. This innovation could significantly boost the accessibility and effectiveness of Photothermal Therapy (PTT)—a technique that destroys cancer cells by heating them with laser light. The research team, comprising experts from the Institute of Nano Science and Technology (INST), Mohali, the Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, and IIT-Bombay, has developed PEGylated semi-shells (SS)—nano-cup structures partially coated with polyethylene glycol (PEG). This coating enhances the particles’ compatibility with the human body, improving their stability and circulation when injected into the bloodstream. Unlike traditional methods that relied on multiple steps and hazardous chemicals like hydrofluoric acid, the new approach is both simpler and safer. Published in Communications Chemistry, a journal by the Nature group, the study outlines a single-step synthesis using biocompatible substances under mild conditions. The researchers used ZIF-8, a metal-organic framework, as a dissolvable template. As ZIF-8 breaks down, gold nanoparticles form around it, resulting in the distinctive nano-cup shape. The process, remarkably, is carried out at room temperature using ascorbic acid (Vitamin C) as a gentle reducing agent. What makes these nano-cups particularly powerful is their ability to absorb and scatter light in the near-infrared (NIR) spectrum, making them highly suitable for PTT. Laboratory experiments showed that the PEGylated semi-shells had high photothermal conversion efficiency, remained stable in water, and were non-toxic. In preclinical trials, the team successfully applied this technology to treat metastatic breast tumors in mice, achieving significant tumor reduction, improved survival rates, and a lower risk of recurrence. Beyond cancer treatment, scientists believe the unique optical features of these nano-cups could pave the way for advanced biosensing applications such as Surface-Enhanced Raman Spectroscopy (SERS). Future studies aim to explore combining this technique with traditional chemotherapy to further enhance cancer treatment outcomes. This homegrown innovation marks a promising step forward in India’s contribution to global cancer therapy, blending cutting-edge nanotechnology with safe, sustainable scientific practices. Source: Economic Times  

Indian Researchers Pioneer Breakthrough Nano-Cup Technology for Heat-Based Cancer Treatment Read More »